SpectRx and Welch Allyn Receive Grant From the National Cancer Institute For Non-invasive Cervical Cancer Detection Device

Apr 24, 2001, 01:00 ET from SpectRx, Inc.

    SKANEATELES FALLS, N.Y. and NORCROSS, Ga., April 24 /PRNewswire
 Interactive News Release/ -- Welch Allyn, Inc. and SpectRx, Inc.
 (Nasdaq:   SPRX) today announced the two companies have received a grant from
 the National Cancer Institute (NCI) to develop a biophotonic non-invasive
 cervical cancer product, which in clinical studies has shown to be more
 effective in identifying cancers and precancers than conventional Pap tests.
 The grant will be used to help determine the optimum hardware and software
 configurations of the product to detect precancerous and cancerous conditions
 of the cervix in real-time.
     According to a NCI review of the technology, the grant was awarded in part
 because "the societal value is very high," "the market is large" and the
 approach "offers advantages to lesion detection because each measurement
 results from different physical origins."  "Improvement in lesion detection
 and identification for cervical cancer diagnosis would result in improved
 patient healthcare and savings to the system of healthcare," according to an
 NCI reviewer.
     Worldwide there are approximately 371,000 cases of cervical cancer
 diagnosed annually and approximately 190,000 deaths per year.  SpectRx and
 Welch Allyn estimate the global market size at approximately $1.6 billion
 annually.  Approximately 60 million Pap tests are performed in the U.S.
 annually.
     The device uses proprietary biophotonic technology to locate cancers and
 precancers painlessly and non-invasively by analyzing light reflected from the
 cervix.  The reflected light creates an image of the cervix indicating the
 location and severity of disease.
     The technology distinguishes between normal and diseased tissue by
 detecting biochemical and morphological changes at the cellular level.  Early
 clinical devices found 31 percent more cervical precancerous lesions than
 conventional Pap tests in studies conducted at two U.S. research centers.
 Unlike current screening methods, the SpectRx/Welch Allyn approach does not
 require a tissue sample or laboratory analysis.
     The National Cancer Institute is the Federal Government's principal agency
 for cancer research.  The award is a Small Business Innovation Research Phase
 1 grant for approximately $100,000.
     Welch Allyn, Inc. was founded in 1915 and is today a leading manufacturer
 of innovative medical devices and miniature precision lamps.  Headquartered in
 Skaneateles Falls, New York, U.S.A., Welch Allyn, Inc. has more than 2,200
 employees and numerous manufacturing, sales, and distribution facilities
 located throughout the world.  For more information on Welch Allyn visit
 www.welchallyn.com .
     SpectRx, a specialty point-of-care medical technology company, develops
 and manufactures non-invasive and minimally invasive diagnostic and monitoring
 systems.  The company employs leading-edge biophotonics, or the use of light
 and spectral energies, to develop painless point-of-care alternatives to
 blood- and tissue-based procedures.  Through internal product development and
 partnerships with major health care companies, SpectRx focuses on key niche
 and large diagnostic markets, primarily oncology, endocrinology and
 neonatology.  The Company's handheld, FDA-cleared BiliChek(TM) (sold
 internationally as BiliCheck(TM)) is the first commercially available non-
 invasive painless monitor for infant jaundice.  Under development are products
 for the non-invasive detection of cervical cancer and Type II diabetes, and a
 consumer device for continuous glucose monitoring.  For more information,
 visit SpectRx's web sites at www.spectrx.com and www.bilicheck.com , or use
 Internet Keyword spectrx .
 
     "Safe Harbor" Statement under the Private Securities Litigation Reform Act
 of 1995.  Certain matters and subject areas discussed in this press release
 that are not historical or current facts deal with potential future
 circumstances and developments.  The discussion of such matters and subject
 areas is qualified by the inherent risks and uncertainties surrounding future
 expectations generally and also may materially differ from SpectRx's actual
 future experience involving any of or more of such matters and subject areas.
 Such risks and uncertainties include overall economic trends, successful
 development of new products and regulatory matters as well as those that are
 more fully described from time to time in SpectRx's reports filed with the SEC
 under the heading "Risk Factors," including SpectRx's Annual Report on Form
 10-K for the fiscal year ended December 31, 2000 and in the Forms 10-Q for the
 first, second and third quarters of 2000 filed by SpectRx.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X01585222
 
 

SOURCE SpectRx, Inc.
    SKANEATELES FALLS, N.Y. and NORCROSS, Ga., April 24 /PRNewswire
 Interactive News Release/ -- Welch Allyn, Inc. and SpectRx, Inc.
 (Nasdaq:   SPRX) today announced the two companies have received a grant from
 the National Cancer Institute (NCI) to develop a biophotonic non-invasive
 cervical cancer product, which in clinical studies has shown to be more
 effective in identifying cancers and precancers than conventional Pap tests.
 The grant will be used to help determine the optimum hardware and software
 configurations of the product to detect precancerous and cancerous conditions
 of the cervix in real-time.
     According to a NCI review of the technology, the grant was awarded in part
 because "the societal value is very high," "the market is large" and the
 approach "offers advantages to lesion detection because each measurement
 results from different physical origins."  "Improvement in lesion detection
 and identification for cervical cancer diagnosis would result in improved
 patient healthcare and savings to the system of healthcare," according to an
 NCI reviewer.
     Worldwide there are approximately 371,000 cases of cervical cancer
 diagnosed annually and approximately 190,000 deaths per year.  SpectRx and
 Welch Allyn estimate the global market size at approximately $1.6 billion
 annually.  Approximately 60 million Pap tests are performed in the U.S.
 annually.
     The device uses proprietary biophotonic technology to locate cancers and
 precancers painlessly and non-invasively by analyzing light reflected from the
 cervix.  The reflected light creates an image of the cervix indicating the
 location and severity of disease.
     The technology distinguishes between normal and diseased tissue by
 detecting biochemical and morphological changes at the cellular level.  Early
 clinical devices found 31 percent more cervical precancerous lesions than
 conventional Pap tests in studies conducted at two U.S. research centers.
 Unlike current screening methods, the SpectRx/Welch Allyn approach does not
 require a tissue sample or laboratory analysis.
     The National Cancer Institute is the Federal Government's principal agency
 for cancer research.  The award is a Small Business Innovation Research Phase
 1 grant for approximately $100,000.
     Welch Allyn, Inc. was founded in 1915 and is today a leading manufacturer
 of innovative medical devices and miniature precision lamps.  Headquartered in
 Skaneateles Falls, New York, U.S.A., Welch Allyn, Inc. has more than 2,200
 employees and numerous manufacturing, sales, and distribution facilities
 located throughout the world.  For more information on Welch Allyn visit
 www.welchallyn.com .
     SpectRx, a specialty point-of-care medical technology company, develops
 and manufactures non-invasive and minimally invasive diagnostic and monitoring
 systems.  The company employs leading-edge biophotonics, or the use of light
 and spectral energies, to develop painless point-of-care alternatives to
 blood- and tissue-based procedures.  Through internal product development and
 partnerships with major health care companies, SpectRx focuses on key niche
 and large diagnostic markets, primarily oncology, endocrinology and
 neonatology.  The Company's handheld, FDA-cleared BiliChek(TM) (sold
 internationally as BiliCheck(TM)) is the first commercially available non-
 invasive painless monitor for infant jaundice.  Under development are products
 for the non-invasive detection of cervical cancer and Type II diabetes, and a
 consumer device for continuous glucose monitoring.  For more information,
 visit SpectRx's web sites at www.spectrx.com and www.bilicheck.com , or use
 Internet Keyword spectrx .
 
     "Safe Harbor" Statement under the Private Securities Litigation Reform Act
 of 1995.  Certain matters and subject areas discussed in this press release
 that are not historical or current facts deal with potential future
 circumstances and developments.  The discussion of such matters and subject
 areas is qualified by the inherent risks and uncertainties surrounding future
 expectations generally and also may materially differ from SpectRx's actual
 future experience involving any of or more of such matters and subject areas.
 Such risks and uncertainties include overall economic trends, successful
 development of new products and regulatory matters as well as those that are
 more fully described from time to time in SpectRx's reports filed with the SEC
 under the heading "Risk Factors," including SpectRx's Annual Report on Form
 10-K for the fiscal year ended December 31, 2000 and in the Forms 10-Q for the
 first, second and third quarters of 2000 filed by SpectRx.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X01585222
 
 SOURCE  SpectRx, Inc.